Results 271 to 280 of about 195,243 (312)

A case report focusing on diagnosis and intervention of chronic myeloid leukemia in blast crisis (acute megakaryoblastic leukemia subtype). [PDF]

Front Oncol
Liu L, Xiao Y, Cui N, Zhang L, Wang L, Gao C, Shi J, Yuan C, Cui C.   +8 more
europepmc   +1 more source

BMD, CTX-1, and Osteocalcin as Monitoring Parameters of Bone Remodelling in CML Patients Undergoing Imatinib Therapy: From Basic Science to Clinical Perspective

Nurita Indarwulan, Merlyna Savitri, Ami Ashariati, Ugroseno Yudho Bintoro, Muhammad Noor Diansyah, Putu Niken Ayu Amrita, Pradana Zaky Romadhon   +6 more
openalex   +2 more sources

Reshape memory T cell landscape in CML patients' blood by tyrosine kinase inhibitors. [PDF]

Caspian J Intern Med
Kareem HA, Ghadi HH.
europepmc   +1 more source

Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023. [PDF]

Cancer
Fan Z, Chen QW, Huang XY, Fu Q, Mai HR, Long XJ, Li QR, Liu LL, Liu RY, He F, Guo BY, Zeng MH, Wan WQ, Zhang WN, Guo HX, Zhou DH, Zou YW, Xiong WJ, Zhou XB, Chen HQ, Lin LM, Ren HY, Tian X, Wei HY, Lan HK, Jin J, Liang C, Luo XQ, Huang LB, Yang LH, Zhang XL.   +30 more
europepmc   +1 more source

Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML. [PDF]

Front Oncol
Schroer AE, Javadi T, Mehta A, Torlak F, McFarland JR, Kumar G, da Silva AL, Benjamin J, Choudhary MM, Sadeghi A, le Coutre P, Blaha MJ, Berning P, Dzaye O.   +13 more
europepmc   +1 more source

Large language models versus classical machine learning performance in COVID-19 mortality prediction using high-dimensional tabular data. [PDF]

Sci Rep
Ghaffarzadeh-Esfahani M, Ghaffarzadeh-Esfahani M, Salahi-Niri A, Toreyhi H, Atf Z, Mohsenzadeh-Kermani A, Sarikhani M, Tajabadi Z, Shojaeian F, Bagheri MH, Feyzi A, Tarighat-Payma M, Gazmeh N, Heydari F, Afshar H, Allahgholipour A, Alimardani F, Salehi A, Asadimanesh N, Khalafi MA, Shabanipour H, Moradi A, Zadeh SH, Yazdani O, Esbati R, Maleki M, Nasr DS, Soheili A, Majlesi H, Shahsavan S, Soheilipour A, Goudarzi N, Taherifard E, Hatamabadi H, Samaan JS, Savage T, Sakhuja A, Soroush A, Nadkarni G, Darazam IA, Pourhoseingholi MA, Safavi-Naini SAA.   +41 more
europepmc   +1 more source

mTOR inhibition by AZD2014 alleviates BCR::ABL1 independent imatinib resistance through enhancing autophagy in CML resistant cells

Wei He
openalex   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

CML Chapter

2021
The discovery of the tyrosine kinase inhibitor (TKI) imatinib in the early 2000's revolutionized the treatment and prognosis of patients with chronic myeloid leukemia (CML) [Hochhaus et al. in N Engl J Med 376:917-927, 2017]. The treatment of patients with CML has changed dramatically since the approval of imatinib and other TKIs.
openaire   +2 more sources